Naglazyme

“While we see potential approval of two products this year and meaningful pipeline progress, we continue to believe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is relatively expensive as it consistently trades at the top of peers,” Wedbush’s Liana Moussatos said in a note, while...